NEW YORK, June 18, 2026, 15:24 (EDT)
- CervoMed shares lately traded up $0.33 at $4.14. They earlier hit $7.75 in the session, with more than 105 million shares changing hands.
- CervoMed said it got a U.S. patent allowance for neflamapimod in “pure” dementia with Lewy bodies. The company expects the patent to run until 2042. CervoMed
- CervoMed said it is selling 2.5 million shares at $4 apiece in a $10 million registered direct offering set to close around June 22.
CervoMed Inc. shares pulled back Thursday, erasing much of an earlier jump linked to a patent development. The Boston biotech quickly announced a $10 million stock offering, flipping the mood. Investors were left to consider potential IP gains next to the hit from dilution.
The stock was recently up 8.7% at $4.14. Earlier in the session, shares hit $7.75, more than twice the previous close. Trading topped 105 million shares. That’s active for a company with a $38 million market cap.
CervoMed needs to keep cash levels up as it pushes its oral dementia drug neflamapimod toward late-stage trials in patients with dementia with Lewy bodies, or DLB. DLB affects thinking, movement and behavior as it gets worse. Right now, CervoMed says there are still no approved DLB drugs in the U.S. or EU.
Nasdaq will close on Friday, June 19, for Juneteenth, so Thursday wraps up the last regular U.S. equity session ahead of the long weekend. The market is working with a shorter week.
CervoMed got a notice of allowance from the U.S. Patent and Trademark Office for neflamapimod’s use in DLB patients who don’t have the Alzheimer’s disease-like tau protein. The company refers to this group as “pure DLB.” CervoMed said the patent should protect neflamapimod for that use until 2042, with a possible extension. CervoMed
CervoMed has lined up new financing. The company said it signed deals to sell 2.5 million common shares at $4 apiece in a registered direct offering. That means the shares go straight to chosen investors, not the broader public. H.C. Wainwright is acting as placement agent. CervoMed said proceeds are set for working capital and general corporate uses.
Patent news kicked off the usual small biotech cycle, followed by a funding question. Shares priced the offering near later trading levels. That slowed the early rally and set a new benchmark for the stock.
CervoMed last week said it lined up a $10.5 million private placement, which the company expects will push its cash runway out to the second quarter of 2027 and support its hunt for a Phase 3 DLB partner. CEO John Alam described the Phase 3 program as a “compelling opportunity for a strategic partner.” Board chair Joshua Boger said DLB is still a “substantial unfulfilled need.” CervoMed
Competition isn’t heavy in this space. Cognition Therapeutics is in the DLB race too. In May, the company said it met with the FDA about zervimesine, or CT1812, for DLB with psychosis. CEO Lisa Ricciardi described the meeting as “productive.” The drug is still investigational. Cognition plans to move it into a late-stage trial. GlobeNewswire
The risk is clear. The deal needs to close, and CervoMed still has to line up a partner or fresh funds to run any Phase 3 DLB study. The company flags worries about cash, trial outcomes, regulatory response and patent upkeep as real risks. Bad data or delays finding a partner could leave the patent extension as just optionality.
Nothing doing in the wider biotech space. The iShares Nasdaq Biotechnology ETF slipped 0.3%. SPDR S&P Biotech ETF gained 0.4% in the afternoon. So this looks like a CervoMed story, not a move with the group. All eyes shift to Monday’s session, where investors have to figure out whether that $4 financing acts as a backstop, a cap, or just the latest in a choppy range.
